

Avelin Fobang Aghokeng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3072361/publications.pdf>

Version: 2024-02-01

35
papers

1,177
citations

304743

22
h-index

377865

34
g-index

36
all docs

36
docs citations

36
times ranked

1643
citing authors

#	ARTICLE	IF	CITATIONS
1	Short Communication: Nucleoside Reverse Transcriptase Inhibitors with Reduced Predicted Activity Do Not Impair Second-Line Therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 477-480.	1.1	4
2	Prevalence of pretreatment HIV drug resistance in Cameroon following a nationally representative WHO survey. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2468-2474.	3.0	14
3	Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12) Tj ETQq1, 1.0.784314 rgBT 63 e384-e392.	4.7	14
4	Field evaluation of an open and polyvalent universal HIV-1/SIVcpz/SIVgor quantitative RT-PCR assay for HIV-1 viral load monitoring in comparison to Abbott RealTime HIV-1 in Cameroon. <i>Journal of Virological Methods</i> , 2016, 237, 121-126.	2.1	3
5	Short Communication: High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1159-1162.	1.1	28
6	Benefits of task-shifting HIV care to nurses in terms of health-related quality of life in patients initiating antiretroviral therapy in rural district hospitals in Cameroon [Stratall Agence Nationale de Recherche sur le SIDA (ANRS) 12110/Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau (ESTHER) substudy]. <i>HIV Medicine</i> , 2015, 16, 307-318.	2.2	15
7	Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa. <i>Aids</i> , 2015, 29, 1473-1481.	2.2	39
8	Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1517-1521.	3.0	9
9	HIV-1 group O infection in Cameroon from 2006 to 2013: Prevalence, genetic diversity, evolution and public health challenges. <i>Infection, Genetics and Evolution</i> , 2015, 36, 210-216.	2.3	22
10	Challenges of Antiretroviral Treatment Monitoring in Rural and Remote-Access Regions in Africa. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 623-625.	1.1	7
11	Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon. <i>HIV Medicine</i> , 2014, 15, 478-487.	2.2	44
12	Field Evaluation of Dried Blood Spots for Routine HIV-1 Viral Load and Drug Resistance Monitoring in Patients Receiving Antiretroviral Therapy in Africa and Asia. <i>Journal of Clinical Microbiology</i> , 2014, 52, 578-586.	3.9	60
13	Extraordinary Heterogeneity of Virological Outcomes in Patients Receiving Highly Antiretroviral Therapy and Monitored With the World Health Organization Public Health Approach in Sub-Saharan Africa and Southeast Asia. <i>Clinical Infectious Diseases</i> , 2014, 58, 99-109.	5.8	83
14	Prediction of HIV Drug Resistance Based on Virologic, Immunologic, Clinical, and/or Adherence Criteria in the Stratall ANRS 12110/ESTHER Trial in Cameroon. <i>Clinical Infectious Diseases</i> , 2013, 57, 604-607.	5.8	6
15	Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 577-586.	9.1	39
16	Genotyping and antifungal susceptibility testing of <i>Cryptococcus neoformans</i> isolates from Cameroonian HIV-positive adult patients. <i>Clinical Microbiology and Infection</i> , 2013, 19, 763-769.	6.0	25
17	Successful Integrase Inhibitor-Based Highly Active Antiretroviral Therapy for a Multidrug-Class-Resistant HIV Type 1 Group O-Infected Patient in Cameroon. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1-3.	1.1	21
18	Task Shifting HIV Care in Rural District Hospitals in Cameroon. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, 569-576.	2.1	26

#	ARTICLE	IF	CITATIONS
19	Time Patterns of Adherence and Long-Term Virological Response to Non-Nucleoside Reverse Transcriptase Inhibitor Regimens in the Stratall Anrs 12110/Esther Trial in Cameroon. <i>Antiviral Therapy</i> , 2013, 18, 29-37.	1.0	20
20	Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon. <i>Journal of the International AIDS Society</i> , 2013, 16, 18004.	3.0	32
21	Susceptibility to Transmitting HIV in Patients Initiating Antiretroviral Therapy in Rural District Hospitals in Cameroon (Stratall ANRS 12110/ESTHER Trial). <i>PLoS ONE</i> , 2013, 8, e62611.	2.5	7
22	Lamivudine-Resistant HBV Infection in HIV-Positive Patients Receiving Antiretroviral Therapy in a Public Routine Clinic in Cameroon. <i>Antiviral Therapy</i> , 2012, 17, 321-326.	1.0	31
23	Noninvasive Follow-Up of Simian Immunodeficiency Virus Infection in Wild-Living Nonhabituated Western Lowland Gorillas in Cameroon. <i>Journal of Virology</i> , 2012, 86, 9760-9772.	3.4	26
24	Adherence as a Predictor of Sexual Behaviors in People Living with HIV/AIDS during the First Year of Antiretroviral Therapy in Rural Cameroon: Data from Stratall ANRS 12110/ESTHER Trial. <i>PLoS ONE</i> , 2012, 7, e36118.	2.5	9
25	Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 825-833.	9.1	83
26	Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naïve patients. <i>Aids</i> , 2011, 25, 2183-2188.	2.2	62
27	High Failure Rate of the ViroSeq HIV-1 Genotyping System for Drug Resistance Testing in Cameroon, a Country with Broad HIV-1 Genetic Diversity. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1635-1641.	3.9	27
28	Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions. <i>Infection, Genetics and Evolution</i> , 2010, 10, 386-396.	2.3	100
29	Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays. <i>Clinical Microbiology and Infection</i> , 2010, 16, 1525-1531.	6.0	38
30	WHO clinical criteria-based initiation of antiretroviral therapy: lessons from rural district hospitals in Cameroon with regard to 2009 revised WHO recommendations. <i>Tropical Medicine and International Health</i> , 2010, 15, 580-3.	2.3	6
31	Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in Cameroon. <i>PLoS ONE</i> , 2009, 4, e7702.	2.5	72
32	Low Prevalence of HIV Type 1 Drug Resistance Mutations in Untreated, Recently Infected Patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: The ANRS 12134 Study. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 1193-1196.	1.1	40
33	Low Levels of Antiretroviral-Resistant HIV Infection in a Routine Clinic in Cameroon that Uses the World Health Organization (WHO) Public Health Approach to Monitor Antiretroviral Treatment and Adequacy with the WHO Recommendation for Second-Line Treatment. <i>Clinical Infectious Diseases</i> , 2009, 48, 1318-1322.	5.8	62
34	Enfuvirtide Binding Domain Is Highly Conserved in Non-B HIV Type 1 Strains from Cameroon, West Central Africa. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 430-433.	1.1	22
35	Evaluation of Four Simple/Rapid Assays and Two Fourth-Generation ELISAs for the Identification of HIV Infection on a Serum Panel Representing the HIV-1 Group M Genetic Diversity in Cameroon. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 37, 1632-1640.	2.1	32